The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Design of antisense oligonucleotides stabilized by locked nucleic acids
Open accessAbstract
The design of antisense oligonucleotides containing locked nucleic acids (LNA) was optimized and compared to intensively studied DNA oligonucleotides, phosphorothioates and 2'-O-methyl gapmers. In contradiction to the literature, a stretch of seven or eight DNA monomers in the center of a chimeric DNA/LNA oligonucleotide is necessary for full activation of RNase H to cleave the target RNA. For 2'-O-methyl gapmers a stretch of six DNA monomers is sufficient to recruit RNase H. Compared to the 18mer DNA the oligonucleotides containing LNA have an increased melting temperature of 1.5-4 degrees C per LNA depending on the positions of the modified residues. 2'-O-methyl nucleotides increase the T(m) by only <1 degree C per modification and the T(m) of the phosphorothioate is reduced. The efficiency of an oligonucleotide in supporting RNase H cleavage correlates with its affinity for the target RNA, i.e. LNA > 2'-O-methyl > DNA > phosphorothioate. Three LNAs at each end of the oligonucleotide are sufficient to stabilize the oligonucleotide in human serum 10-fold compared to an unmodified oligodeoxynucleotide (from t(1/2) = approximately 1.5 h to t(1/2) = approximately 15 h). These chimeric LNA/DNA oligonucleotides are more stable than isosequential phosphorothioates and 2'-O-methyl gapmers, which have half-lives of 10 and 12 h, respectively.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cloned Capsaicin Receptor Integrates Multiple Pain-Producing Stimuli
Tominaga, M., Caterina, M. J., Malmberg, A. B., Rosen, T. A., Gilbert, H., Skinner, K., Raumann, B. E., Basbaum, A. I., & Julius, D. (1998) · Neuron · doi:10.1016/s0896-6273(00)80564-4 · Cited by 3,081
A capsaicin-receptor homologue with a high threshold for noxious heat
Caterina, M. J., Rosen, T. A., Tominaga, M., Brake, A. J., & Julius, D. (1999) · Nature · doi:10.1038/18906 · Cited by 1,603
Koshkin, A. A., Singh, S. K., Nielsen, P., Rajwanshi, V. K., Kumar, R., Meldgaard, M., Olsen, C. E., & Wengel, J. (1998) · Tetrahedron · doi:10.1016/s0040-4020(98)00094-5 · Cited by 1,047
Monia, B. P., Lesnik, E. A., Gonzalez, C., Lima, W. F., McGee, D., Guinosso, C. J., Kawasaki, A. M., Cook, P. D., & Freier, S. M. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)85268-7 · Cited by 778
Obika, S., Nanbu, D., Hari, Y., Andoh, J.-I., Morio, K.-I., Doi, T., & Imanishi, T. (1998) · Tetrahedron Letters · doi:10.1016/s0040-4039(98)01084-3 · Cited by 700
Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA
Braasch, D. A., & Corey, D. R. (2001) · Chemistry & Biology · doi:10.1016/s1074-5521(00)00058-2 · Cited by 605
Potent and nontoxic antisense oligonucleotides containing locked nucleic acids
Wahlestedt, C., Salmi, P., Good, L., Kela, J., Johnsson, T., Hökfelt, T., Broberger, C., Porreca, F., Lai, J., Ren, K., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.10.5633 · Cited by 520
Levin, A. A. (1999) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(99)00140-2 · Cited by 438
Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding.
Brown, D. A., Kang, S. H., Gryaznov, S. M., DeDionisio, L., Heidenreich, O., Sullivan, S., Xu, X., & Nerenberg, M. I. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47090-1 · Cited by 336
Guvakova, M. A., Yakubov, L. A., Vlodavsky, I., Tonkinson, J. L., & Stein, C. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.6.2620 · Cited by 326
Cited by
MicroRNA-21 Is an Antiapoptotic Factor in Human Glioblastoma Cells
Chan, J. A., Krichevsky, A. M., & Kosik, K. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0137 · Cited by 2,557
The current state and future directions of RNAi-based therapeutics
Setten, R. L., Rossi, J. J., & Han, S.-P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0017-4 · Cited by 1,443
Bennett, C. F., & Swayze, E. E. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,374
Antisense technologies: Improvement through novel chemical modifications
Kurreck, J. (2003) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2003.03555.x · Cited by 1,006
Self-citationValoczi, A. (2004) · Nucleic Acids Research · doi:10.1093/nar/gnh171 · Cited by 866
Antisense technology: an overview and prospectus
Crooke, S. T., Baker, B. F., Crooke, R. M., & Liang, X.-H. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00162-z · Cited by 775
LNA (Locked Nucleic Acid): High-Affinity Targeting of Complementary RNA and DNA
Vester, B., & Wengel, J. (2004) · Biochemistry · doi:10.1021/bi0485732 · Cited by 727
Targeting noncoding RNAs in disease
Adams, B. D., Parsons, C., Walker, L., Zhang, W. C., & Slack, F. J. (2017) · Journal of Clinical Investigation · doi:10.1172/jci84424 · Cited by 673
RNA-based therapeutics: an overview and prospectus
Zhu, Y., Zhu, L., Wang, X., & Jin, H. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05075-2 · Cited by 623
LNA: a versatile tool for therapeutics and genomics
Petersen, M., & Wengel, J. (2003) · Trends in Biotechnology · doi:10.1016/s0167-7799(02)00038-0 · Cited by 613
Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality
Elm n, J. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki193 · Cited by 559
Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development
Dhuri, K., Bechtold, C., Quijano, E., Pham, H., Gupta, A., Vikram, A., & Bahal, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9062004 · Cited by 545
Homeostatic regulation of MeCP2 expression by a CREB-induced microRNA
Klein, M. E., Lioy, D. T., Ma, L., Impey, S., Mandel, G., & Goodman, R. H. (2007) · Nature Neuroscience · doi:10.1038/nn2010 · Cited by 444
ANTISENSE OLIGONUCLEOTIDES: FROM DESIGN TO THERAPEUTIC APPLICATION
Chan, J. H., Lim, S., & Wong, W. F. (2006) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2006.04403.x · Cited by 430
Pharmacology of Antisense Drugs
Bennett, C. F., Baker, B. F., Pham, N., Swayze, E., & Geary, R. S. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104846 · Cited by 425
Functionalized DNA Nanostructures
Wilner, O. I., & Willner, I. (2012) · Chemical Reviews · doi:10.1021/cr200104q · Cited by 399
LNA-modified oligonucleotides mediate specific inhibition of microRNA function
Ørom, U. A., Kauppinen, S., & Lund, A. H. (2006) · Gene · doi:10.1016/j.gene.2005.12.031 · Cited by 373
RNA Interference Functions as an Antiviral Immunity Mechanism in Mammals
Li, Y., Lu, J., Han, Y., Fan, X., & Ding, S.-W. (2013) · Science · doi:10.1126/science.1241911 · Cited by 365
Advancement of the emerging field of RNA nanotechnology
Jasinski, D., Haque, F., Binzel, D. W., & Guo, P. (2017) · ACS Nano · doi:10.1021/acsnano.6b05737 · Cited by 352
Discovering the first microRNA-targeted drug
Lindow, M., & Kauppinen, S. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201208082 · Cited by 302
Recent progress in non-native nucleic acid modifications
McKenzie, L. K., El-Khoury, R., Thorpe, J. D., Damha, M. J., & Hollenstein, M. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01430c · Cited by 300
Delivering the promise of miRNA cancer therapeutics
Pereira, D. M., Rodrigues, P. M., Borralho, P. M., & Rodrigues, C. M. P. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2012.10.002 · Cited by 288
Application of locked nucleic acids to improve aptamer in vivo stability and targeting function
Schmidt, K. S. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh862 · Cited by 287
Antisense oligonucleotides in therapy for neurodegenerative disorders
Evers, M. M., Toonen, L. J. A., & van Roon-Mom, W. M. C. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.03.008 · Cited by 286
Perspectives on Chemistry and Therapeutic Applications of Locked Nucleic Acid (LNA)
Kaur, H., Babu, B. R., & Maiti, S. (2007) · Chemical Reviews · doi:10.1021/cr050266u · Cited by 285
Nano-flares for mRNA Regulation and Detection
Prigodich, A. E., Seferos, D. S., Massich, M. D., Giljohann, D. A., Lane, B. C., & Mirkin, C. A. (2009) · ACS Nano · doi:10.1021/nn9003814 · Cited by 284
Campbell, M. A., & Wengel, J. (2011) · Chemical Society Reviews · doi:10.1039/c1cs15048k · Cited by 279
Grunweller, A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg409 · Cited by 269
Noncoding RNAs in cancer therapy resistance and targeted drug development
Wang, W.-T., Han, C., Sun, Y.-M., Chen, T.-Q., & Chen, Y.-Q. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0748-z · Cited by 265
Regulation of NF-κB inhibitor IκBα and viral replication by a KSHV microRNA
Lei, X., Bai, Z., Ye, F., Xie, J., Kim, C.-G., Huang, Y., & Gao, S.-J. (2010) · Nature Cell Biology · doi:10.1038/ncb2019 · Cited by 264
Histone Modifications and Non-Coding RNAs: Mutual Epigenetic Regulation and Role in Pathogenesis
Bure, I. V., Nemtsova, M. V., & Kuznetsova, E. B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105801 · Cited by 253
DNA damage-induced cell death relies on SLFN11-dependent cleavage of distinct type II tRNAs
Li, M., Kao, E., Malone, D., Gao, X., Wang, J. Y. J., & David, M. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0142-5 · Cited by 136
Weng, S.-Y., Wang, X., Vijayan, S., Tang, Y., Kim, Y. O., Padberg, K., Regen, T., Molokanova, O., Chen, T., Bopp, T., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.01.028 · Cited by 128
microRNA-132 regulates gene expression programs involved in microglial homeostasis
Walgrave, H., Penning, A., Tosoni, G., Snoeck, S., Davie, K., Davis, E., Wolfs, L., Sierksma, A., Mars, M., Bu, T., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106829 · Cited by 41
Unveiling the potential of antisense oligonucleotides: Mechanisms, therapies, and safety insights
Ersöz, E., & Demir‐Dora, D. (2024) · Drug Development Research · doi:10.1002/ddr.22187 · Cited by 34
“Consequently, the viscosity rise impacts the maximum dosage that can be administered via a single subcutaneous (sc) injection (Kurreck, 2002).”
BackgroundPandey, M., Ojha, D., Bansal, S., Rode, A. B., & Chawla, G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101003 · Cited by 23
Mouse microRNA-124 regulates the expression of Hes1 in P19 cells
Ma, X. (2010) · Frontiers in Bioscience · doi:10.2741/e74 · Cited by 21
Metadata
- Authors
- Kurreck, J.
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-05-01
- Volume
- 30
- Issue
- 9
- Pages
- 1911-1918
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- OpenAlex
- W2129932149
- Cited by
- 577
- References
- 27
- FWCI
- 8.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.